When was Starpharma founded?

Starpharma was founded in 1996 and raised its 1st funding round 11 years after it was founded.

Where is Starpharma located?

Starpharma is headquartered in United States.

How many employees does Starpharma have?

As of Jul 31, 2026, the latest employee count at Starpharma is 81.

Is Starpharma a funded company?

Starpharma is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 27, 2007.

When was the latest funding round of Starpharma?

Starpharma's latest funding was a $***** Post IPO round on Sep 30, 2020, with participation from 0 investor. Its primary sector is Nanotechnology. In United States, the Nanotechnology sector has seen $660M in funding in 2026 to date.

Where does Starpharma rank among its competitors?

Starpharma ranks 237th amongst 2750 active competitors, of which 924 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Starpharma?

Starpharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Starpharma - 2026 Company Profile, Funding & Competitors

Company Details

Biotechnology company advancing dendrimer technology for improved patient health outcomes. The company focuses on developing and commercializing innovative products based on its proprietary dendrimer technology platform. This platform enhances drug delivery and effectiveness across various therapeutic areas, particularly oncology and anti-infectives. The company's mission is to address unmet medical needs and improve the quality of life for patients with significant illnesses. They leverage strategic partnerships to develop and commercialize innovative products, creating value for all stakeholders. Their technology offers significant therapeutic and commercial opportunities, driving innovation in the biotechnology and pharmaceutical industries. The company is committed to advancing patient care through next-generation dendrimer technology, with a focus on research, development, and commercialization of novel therapies.

Website: starpharma.com
Social

Key Metrics

Founded Year

1996

Location

United States

Stage

Public

Latest Funding Round

Post IPO, Sep 30, 2020, $*****

Investors

The Australian health system & 1 more

Ranked

237^th among 2750 active competitors

Employee Count

81 as on Jul 31, 2026

Similar Companies

RayzeBio & 464 more

Exit Details

Public

View Starpharma's full profile

Starpharma got listed on Sep 28, 2000.

Click here to take a look at Starpharma's IPO in detail

Starpharma has raised funding over 6 rounds. Its first funding round was on Aug 27, 2007. Starpharma has 2 institutional investors.

Here is the list of recent funding rounds of Starpharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 30, 2020	5882551	Post IPO	1078277	1129069	2511596	9601706
Sep 03, 2020	8365120	Grant (prize money)	3845690	8302088	1802505	The Australian health system
Jan 20, 2016	9490648	Post IPO	9790451	8202573	3111204	9614892

Access funding benchmarks and valuations. Sign up today!

View details of Starpharma's funding rounds and investors

Starpharma's employee count trend

Starpharma has 81 employees as of Jul 26. Here is Starpharma's employee count trend over the years:

Uncover Starpharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Starpharma include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Starpharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
237th	Starpharma 1996, United States, Public	Biotechnology company advancing dendrimer technology for improved patient health outcomes	-	The Australian health system, HHS	57/100